

UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549 FORM 6-KÂ REPORT OF FOREIGN PRIVATE ISSUERÂ PURSUANT TO RULE 13a-16 OR 15d-16UNDER THE SECURITIES EXCHANGE ACT OF 1934Â January 10, 2025Â Commission File Number: 0-29374Â EDAP TMS S.A.Parc Activite La Poudrette Lamartine4/6 Rue du Dauphine69120 Vaulx-en-Velin - FranceÂ Â Indicate by check mark whether the registrant files or will file annual reports under coverof Form 20-F or Form 40-F.Â Form 20-F [ x ] Â Â Â Â Form 40-F [ ]Â Â Â Â

Â SIGNATURESÂ Pursuant to the requirements of the Securities Act of 1934, the registrant has duly caused thisreport to be signed on its behalf by the undersigned, thereunto duly authorized.Â Date: January 10, 2025Â EDAP TMS S.A.Â Â /s/ KEN MOBECKKEN MOBECKCHIEF FINANCIAL OFFICERÂ Â Â EDAP Appoints Joshua H. Levine to Board of DirectorsÂ Â AUSTIN, Texas, January 10, 2025 -- EDAP TMS SA(Nasdaq: EDAP) (â€œthe Companyâ€ or â€œEDAPâ€), the global leader in robotic energy-based therapies, today announcedthe appointment of Joshua H. Levine to its Board of Directors.Â â€œWe are pleased to welcome Josh Levine toour Board of Directors," said Dr. Lance Willsey, Interim Chairman of the Board of EDAP TMS. â€œJosh brings a wealth of executiveexperience and a track record of growing shareholder value by focusing on transformative, high growth business strategies within the medicaltechnology sector. As EDAP continues to grow the market for its leading Focal Oneâ€ robotic HIFU platform, Josh will help shape our strategic vision and execution as we expand our leadership in developing the most advancedHIFU technology applications for addressing multiple therapeutic areas.â€Â â€œI am very excited to join EDAPâ€™sBoard of Directors, particularly at a time when the Focal One platform is clearly transforming the treatment paradigm within prostatecancer,â€ said Josh Levine. â€œOver the last two years, EDAP has made significant progress in establishing Focal One as the dominantand most technologically advanced platform for delivering robotic HIFU. As a member of the Board of Directors, I look forward to workingwith EDAPâ€™s senior executives to help expand this exciting technology which clearly has the potential to transform treatment paradigmsacross a broad range of indications, including endometriosis and BPH.â€Â Mr. Levine is a strategic business leader with decades of diverse globalboard and executive management experience within the medical technology industry. He possesses a deep expertise in portfolio transformation,strategic business development and driving shareholder value. From 2012 to 2022, Mr. Levine served as President, Chief Executive Officer, and Director of Accuray Incorporated, where he led a transformative turnaround that involved all strategic, operational, and financialactivities that restored the business to consistent top line growth, positive operating profit, free cash flow (EBITDA), and expandedthe companyâ€™s global footprint. Before joining Accuray, Mr. Levine served as President, Chief Executive Officer, and Board Memberof Immucor, Inc. (Nasdaq: BLUD), where he led the transition from the company being publicly traded up until its acquisition as a privateentity by TPG Capital in August 2011 for approximately \$2 billion. From 2004 to 2010, Mr. Levine served as President, Chief ExecutiveOfficer and Board Member of Mentor Corporation (NYSE: MNT), where he played an instrumental role in repositioning the company by executinga strategic transformation focused on higher growth markets, ultimately leading to the companyâ€™s acquisition by Johnson & Johnson(J&J) in June 2008 for \$1.2 billion.Â His independent public company director experience began in 2018 at NatusMedical Corporation where he served on the boards audit, compensation, and nominating/governance committees. From 2021-2022 he servedas the non-executive Chairperson of the Board. In July 2022, Natus was acquired by Archimed, a French private equity firm, in a transactionvalued at \$1.2 billion. Mr. Levine currently is the non-executive Chairperson of the Board of Adaptiiv Medical Technologies, a Halifax,NS based venture backed start up in the radiation oncology space. Mr. Levine has completed executive management programs at UCLA AndersonSchool of Business, Stanford University, and University of Pennsylvania, and he received his bachelorâ€™s degree in communicationsfrom the University of Arizona.Â AboutÂ EDAP TMS SAÂ A recognized leader in the robotic energy-basedtherapies,Â EDAP TMSÂ develops, manufactures, promotes and distributes worldwide minimally invasive medical devices for variousconditions using ultrasound technology. By combining the latest technologies in imaging, robotics and precise non-invasive energy delivery,Â EDAP TMSÂ introduced the FocalÂ OneÂ®Â inÂ EuropeÂ and in theÂ U.S.Â as the leading prostate focaltherapy controlled by urologists with the potential to expand to multiple indications beyond prostate cancer. For more information onthe Company, please visitÂ <http://www.edap-tms.com>,Â us.hifu-prostate.comÂ andÂ [www.focalone.com](http://www.focalone.com).Â Â Â Forward-Looking StatementsÂ In addition to historical information, this pressrelease contains forward-looking statements within the meaning of applicable federal securities laws, including Section 27A of theÂ U.S.Â SecuritiesAct of 1933 (the â€œSecurities Actâ€) or Section 21E of theÂ U.S.Â Securities Exchange Act of 1934, which may be identifiedby words such as â€œbelieve,â€ â€œcan,â€ â€œcontemplate,â€ â€œcould,â€ â€œplan,â€ â€œintend,â€ â€œis designed to,â€ â€œmay,â€ â€œmight,â€ â€œpotential,â€ â€œobjective,â€ â€œtarget,â€ â€œproject,â€ â€œpredict,â€ â€œforecast,â€ â€œambition,â€ â€œguideline,â€ â€œshould,â€ â€œwill,â€ â€œestimate,â€ â€œexpectâ€ and â€œanticipate,â€ or the negative of these and similar expressions,which reflect our views about future events and financial performance. Such statements are based on management's current expectationsand are subject to a number of risks and uncertainties, including matters not yet known to us or not currently considered material byus, and there can be no assurance that anticipated events will occur or that the objectives set out will actually be achieved. Importantfactors that could cause actual results to differ materially from the results anticipated in the forward-looking statements include, amongothers, the clinical status and market acceptance of our HIFU devices and the continued market potential for our lithotripsy and distributiondivisions, as well as risks associated with the current worldwide inflationary environment, the uncertain worldwide economic, politicaland financial environment, geopolitical instability, climate change and pandemics like the COVID 19 pandemic, or other public health crises, and their related impact on our business operations, including their impacts across our businesses or demand for our devices and services.Â Other factors that may cause such a differencemay also include, but are not limited to, those described in the Company's filings with theÂ Securities and Exchange CommissionÂ andin particular, in the sections "Cautionary Statement on Forward-Looking Information" and "Risk Factors" in the Company'sAnnual Report on Form 20-F.Â Forward-looking statements speak only as of thedate they are made. Other than required by law, we do not undertake any obligation to update them in light of new information or futuredevelopments. These forward-looking statements are based upon information, assumptions and estimates available to us as of the date ofthis press release, and while we believe such information forms a reasonable basis for such statements, such information may be limitedor incomplete.Â Company ContactBlandine ConfortInvestor Relations / Legal AffairsEDAP TMS SA+33 4 72 15 31 50bconfort@edap-tms.comÂ Investor ContactJohn FrauncesLifeSci Advisors, LLC(917) 355-2395jfraunces@lifesciadvisors.comÂ Â Â